TROPION-Lung01 Study Design and Baseline demographics
Conclusions
.
.
•
Dato-DXd is the first ADC to demonstrate a statistically significant improvement in PFS
over docetaxel in patients with previously treated, locally advanced or metastatic NSCLC
PFS benefit was primarily driven by patients with non-squamous histology
Fewer grade ≥3 TRAES and no new safety signals were observed with Dato-DXd
Grade ≥3 ILD was seen, highlighting the need for careful monitoring and adherence to
ILD management guidelines
The interim OS findings favor Dato-DXd, and the trial is continuing to final analysis
Dato-DXd is a potential new meaningful therapy for patients with previously treated
non-squamous NSCLC
ADC, antibody-drug conjugate; ILD, interstitial lung disease; NSCLC, non-small cell lung cancer, OS, overall survival; PFS, progression-free survival; TRAE, treatment-related adverse event.
Daiichi-Sankyo
16View entire presentation